Literature DB >> 17686848

Crystal structure and structural mechanism of a novel anti-human immunodeficiency virus and D-amino acid-containing chemokine.

Dongxiang Liu1, Navid Madani, Ying Li, Rong Cao, Won-Tak Choi, Sameer P Kawatkar, Mi Youn Lim, Santosh Kumar, Chang-Zhi Dong, Jun Wang, Julie D Russell, Caroline R Lefebure, Jing An, Scott Wilson, Yi-Gui Gao, Luke A Pallansch, Joseph G Sodroski, Ziwei Huang.   

Abstract

Chemokines and their receptors play important roles in normal physiological functions and the pathogeneses of a wide range of human diseases, including the entry of human immunodeficiency virus type 1 (HIV-1). However, the use of natural chemokines to probe receptor biology or to develop therapeutic drugs is limited by their lack of selectivity and the poor understanding of mechanisms in ligand-receptor recognition. We addressed these issues by combining chemical and structural biology in research into molecular recognition and inhibitor design. Specifically, the concepts of chemical biology were used to develop synthetically and modularly modified (SMM) chemokines that are unnatural and yet have properties improved over those of natural chemokines in terms of receptor selectivity, affinity, and the ability to explore receptor functions. This was followed by using structural biology to determine the structural basis for synthetically perturbed ligand-receptor selectivity. As a proof-of-principle for this combined chemical and structural-biology approach, we report a novel D-amino acid-containing SMM-chemokine designed based on the natural chemokine called viral macrophage inflammatory protein II (vMIP-II). The incorporation of unnatural D-amino acids enhanced the affinity of this molecule for CXCR4 but significantly diminished that for CCR5 or CCR2, thus yielding much more selective recognition of CXCR4 than wild-type vMIP-II. This D-amino acid-containing chemokine also showed more potent and specific inhibitory activity against HIV-1 entry via CXCR4 than natural chemokines. Furthermore, the high-resolution crystal structure of this D-amino acid-containing chemokine and a molecular-modeling study of its complex with CXCR4 provided the structure-based mechanism for the selective interaction between the ligand and chemokine receptors and the potent anti-HIV activity of D-amino acid-containing chemokines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17686848      PMCID: PMC2045531          DOI: 10.1128/JVI.02845-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Comparison of the structure of vMIP-II with eotaxin-1, RANTES, and MCP-3 suggests a unique mechanism for CCR3 activation.

Authors:  E J Fernandez; J Wilken; D A Thompson; S C Peiper; E Lolis
Journal:  Biochemistry       Date:  2000-10-24       Impact factor: 3.162

Review 2.  Structure, function, and inhibition of chemokines.

Authors:  Elias J Fernandez; Elias Lolis
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002       Impact factor: 13.820

3.  The solution structure of the anti-HIV chemokine vMIP-II.

Authors:  A C Liwang; Z X Wang; Y Sun; S C Peiper; P J Liwang
Journal:  Protein Sci       Date:  1999-11       Impact factor: 6.725

4.  Structure of bacteriorhodopsin at 1.55 A resolution.

Authors:  H Luecke; B Schobert; H T Richter; J P Cartailler; J K Lanyi
Journal:  J Mol Biol       Date:  1999-08-27       Impact factor: 5.469

5.  Effect of D-amino acid substitution in a mucin 2 epitope on mucin-specific monoclonal antibody recognition.

Authors:  K Uray; J Kajtár; E Vass; M R Price; M Hollósi; F Hudecz
Journal:  Arch Biochem Biophys       Date:  2000-06-01       Impact factor: 4.013

6.  Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies.

Authors:  N Zhou; Z Luo; J Luo; D Liu; J W Hall; R J Pomerantz; Z Huang
Journal:  J Biol Chem       Date:  2001-09-10       Impact factor: 5.157

Review 7.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.

Authors:  E A Berger; P M Murphy; J M Farber
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

8.  Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry.

Authors:  M Farzan; T Mirzabekov; P Kolchinsky; R Wyatt; M Cayabyab; N P Gerard; C Gerard; J Sodroski; H Choe
Journal:  Cell       Date:  1999-03-05       Impact factor: 41.582

9.  Nuclear magnetic resonance solution structure of truncated human GRObeta [5-73] and its structural comparison with CXC chemokine family members GROalpha and IL-8.

Authors:  Y Q Qian; K O Johanson; P McDevitt
Journal:  J Mol Biol       Date:  1999-12-17       Impact factor: 5.469

10.  Molecular modeling and site-directed mutagenesis of CCR5 reveal residues critical for chemokine binding and signal transduction.

Authors:  N Zhou; Z Luo; J W Hall; J Luo; X Han; Z Huang
Journal:  Eur J Immunol       Date:  2000-01       Impact factor: 5.532

View more
  11 in total

Review 1.  Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).

Authors:  Won-Tak Choi; Srinivas Duggineni; Yan Xu; Ziwei Huang; Jing An
Journal:  J Med Chem       Date:  2011-12-02       Impact factor: 7.446

Review 2.  Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.

Authors:  Won-Tak Choi; Yilei Yang; Yan Xu; Jing An
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

3.  The active core in a triazole peptide dual-site antagonist of HIV-1 gp120.

Authors:  Muddegowda Umashankara; Karyn McFadden; Isaac Zentner; Arne Schön; Srivats Rajagopal; Ferit Tuzer; Syna A Kuriakose; Mark Contarino; Judith Lalonde; Ernesto Freire; Irwin Chaiken
Journal:  ChemMedChem       Date:  2010-11-08       Impact factor: 3.466

Review 4.  Biology and clinical relevance of chemokines and chemokine receptors CXCR4 and CCR5 in human diseases.

Authors:  Won-Tak Choi; Jing An
Journal:  Exp Biol Med (Maywood)       Date:  2011-05-12

Review 5.  Discoveries and developments of CXCR4-targeted HIV-1 entry inhibitors.

Authors:  Chaozai Zhang; Ruohan Zhu; Qizhi Cao; Xiaohong Yang; Ziwei Huang; Jing An
Journal:  Exp Biol Med (Maywood)       Date:  2020-02-04

6.  Non-natural peptide triazole antagonists of HIV-1 envelope gp120.

Authors:  Kantharaju Kamanna; Rachna Aneja; Caitlin Duffy; Pamela Kubinski; Diogo Rodrigo Moreira; Lauren D Bailey; Karyn McFadden; Arne Schön; Andrew Holmes; Ferit Tuzer; Mark Contarino; Ernesto Freire; Irwin M Chaiken
Journal:  ChemMedChem       Date:  2012-12-13       Impact factor: 3.466

7.  Structural and Biological Characterizations of Novel High-Affinity Fluorescent Probes with Overlapped and Distinctive Binding Regions on CXCR4.

Authors:  Siyu Zhu; Qian Meng; Robert T Schooley; Jing An; Yan Xu; Ziwei Huang
Journal:  Molecules       Date:  2019-08-13       Impact factor: 4.411

8.  Computational analysis of the structural mechanism of inhibition of chemokine receptor CXCR4 by small molecule antagonists.

Authors:  Sameer P Kawatkar; Maocai Yan; Harsukh Gevariya; Mi Youn Lim; Steven Eisold; Xuejun Zhu; Ziwei Huang; Jing An
Journal:  Exp Biol Med (Maywood)       Date:  2011-06-22

9.  Design, synthesis, and biological characterization of novel PEG-linked dimeric modulators for CXCR4.

Authors:  Yilei Yang; Mei Gao; Qinghao Zhang; Chaozai Zhang; Xiaohong Yang; Ziwei Huang; Jing An
Journal:  Bioorg Med Chem       Date:  2016-08-31       Impact factor: 3.641

10.  Elucidating a key component of cancer metastasis: CXCL12 (SDF-1α) binding to CXCR4.

Authors:  Phanourios Tamamis; Christodoulos A Floudas
Journal:  J Chem Inf Model       Date:  2014-04-08       Impact factor: 4.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.